18889881171
Kalkine 0
countryflagUS

Ansell Limited

Healthcare US ANSLF

18.0USD
-(-%)

Last update at 2025-05-16T13:30:00Z

Day Range

18.0018.00
LowHigh

52 Week Range

14.8721.00
LowHigh

Fundamentals

  • Previous Close 18.00
  • Market Cap3150.39M
  • Volume0
  • P/E Ratio35.25
  • Dividend Yield1.84%
  • EBITDA242.60M
  • Revenue TTM1619.30M
  • Revenue Per Share TTM12.58
  • Gross Profit TTM 616.70M
  • Diluted EPS TTM0.59

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2024-06-30 2023-06-30 2022-06-30 2021-06-30 2020-06-30
Type yearly yearly yearly yearly yearly
Date 2024-06-30 2023-06-30 2022-06-30 2021-06-30 2020-06-30
Income before tax 108.70M 188.67M 205.65M 318.10M 206.00M
Minority interest -1.00000M -1.60000M -1.10000M 13.40M 11.90M
Net income 76.50M 148.30M 158.70M 246.70M 158.70M
Selling general administrative 66.20M 118.13M 79.88M 480.10M 124.38M
Selling and marketing expenses 495.50M 271.55M 295.10M 480.10M 286.17M
Gross profit 624.80M 604.22M 625.19M 810.00M 647.86M
Reconciled depreciation 72.60M 68.00M 65.30M 64.10M 55.59M
Ebit 128.45M 196.67M 225.32M 401.60M 222.90M
Ebitda 202.30M 264.00M 287.45M 401.60M 279.69M
Depreciation and amortization 73.85M 67.33M 62.13M 64.51M 56.80M
Non operating income net other - - - - -
Operating income 129.30M 196.87M 233.62M 401.60M 222.53M
Other operating expenses 1490.00M 1437.20M 1617.20M 1761.10M 1445.39M
Interest expense 25.43M 21.42M 18.87M 19.40M 23.05M
Tax provision 31.20M 39.70M 48.60M 69.80M 61.49M
Interest income 4.40M - - 1.20M 7.14M
Net interest income -20.60000M -19.40000M -19.70000M -18.20000M -23.16771M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense 31.20M 39.20M 46.08M 69.80M 42.69M
Total revenue 1619.30M 1634.07M 1850.82M 2026.90M 1667.92M
Total operating expenses 495.50M 407.36M 391.57M 544.20M 425.33M
Cost of revenue 994.50M 1029.84M 1225.63M 1216.90M 1020.06M
Total other income expense net -20.60000M -20.90000M -28.20000M 8.10M -16.53762M
Discontinued operations - - - - -
Net income from continuing ops 77.50M 149.90M 159.80M 248.30M 233.28M
Net income applicable to common shares - 148.30M 158.70M 246.70M 156.60M
Preferred stock and other adjustments - - - - -
Breakdown 2024-06-30 2023-06-30 2022-06-30 2021-06-30 2020-06-30
Type yearly yearly yearly yearly yearly
Date 2024-06-30 2023-06-30 2022-06-30 2021-06-30 2020-06-30
Total assets 3242.60M 2530.60M 2506.20M 2737.70M 2448.60M
Intangible assets 212.50M 214.40M 1049.40M 225.70M 231.20M
Earning assets - - - - -
Other current assets 41.80M 31.10M 38.10M 37.40M 25.10M
Total liab 1332.40M 915.20M 949.60M 1173.10M 1045.20M
Total stockholder equity 1894.90M 1600.90M 1542.90M 1551.20M 1391.50M
Deferred long term liab - - - - -
Other current liab 111.02M 77.80M 65.80M 171.70M 120.00M
Common stock 1028.20M 750.70M 743.80M 769.00M 806.00M
Capital stock 1028.20M 750.70M 743.80M 769.00M 806.00M
Retained earnings 1059.80M 1026.60M 942.00M 866.80M 705.70M
Other liab - 123.60M 121.70M 128.50M 124.20M
Good will 842.30M 845.30M 834.40M 851.40M 834.70M
Other assets 0.00000M 122.10M 95.80M 114.70M 101.00M
Cash 912.30M 159.40M 206.20M 240.20M 408.90M
Cash and equivalents - - - - -
Total current liabilities 423.40M 414.60M 360.30M 549.90M 408.40M
Current deferred revenue 9.38M - - - -
Net debt -55.10000M 334.90M 279.60M 275.30M 168.60M
Short term debt 77.50M 117.30M 18.20M 20.80M 68.30M
Short long term debt 59.70M 100.00M - - 72.85M
Short long term debt total 857.20M 494.30M 485.80M 515.50M 577.50M
Other stockholder equity -0.00000M -176.40000M -142.90000M -84.60000M -120.20000M
Property plant equipment - 436.80M 356.60M 356.00M 307.00M
Total current assets 1623.90M 912.00M 984.50M 1166.90M 961.00M
Long term investments 5.60M 6.50M 18.00M 21.90M 17.34M
Net tangible assets - 541.20M 493.50M 474.10M 329.00M
Short term investments 7.18M - - - -
Net receivables 211.90M 191.20M 201.70M 274.20M 181.20M
Long term debt 706.60M 307.00M 426.30M 451.70M 684.69M
Inventory 457.90M 526.10M 521.30M 611.20M 340.10M
Accounts payable 225.50M 219.50M 276.30M 357.40M 220.10M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income -193.10000M -176.40000M -142.90000M -84.60000M -120.20000M
Additional paid in capital - - - - -
Common stock total equity - - - - -
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 42.75M 42.00M 32.60M 32.70M 34.30M
Deferred long term asset charges - - - - -
Non current assets total 1618.70M 1618.60M 1521.70M 1570.80M 1487.60M
Capital lease obligations 90.90M 87.30M 59.50M 63.80M 83.93M
Long term debt total - - - - -
Breakdown 2024-06-30 2023-06-30 2022-06-30 2021-06-30 2020-06-30
Type yearly yearly yearly yearly yearly
Date 2024-06-30 2023-06-30 2022-06-30 2021-06-30 2020-06-30
Investments -63.40000M -75.50000M -5.10000M -1.70000M -11.90000M
Change to liabilities - -78.90000M -94.70000M 124.20M 35.70M
Total cashflows from investing activities - -75.50000M -71.20000M -84.70000M -70.60000M
Net borrowings - -59.50000M -17.10000M -112.10000M -37.90000M
Total cash from financing activities 540.80M -149.20000M -176.70000M -267.50000M -198.30000M
Change to operating activities - 0.70M -48.90000M 16.10M 6.80M
Net income 77.82M 148.30M 158.70M 246.70M 156.60M
Change in cash 752.90M -46.80000M -34.00000M -168.70000M 11.40M
Begin period cash flow 159.40M 206.20M 240.20M 408.90M 397.50M
End period cash flow 912.30M 159.40M 206.20M 240.20M 408.90M
Total cash from operating activities 272.30M 180.50M 222.00M 172.80M 290.90M
Issuance of capital stock 305.20M -0.30000M 103.20M - -
Depreciation 73.85M 68.00M 60.20M 57.40M 50.70M
Other cashflows from investing activities - 2.70M 2.70M 2.70M 2.70M
Dividends paid 53.20M 62.90M 86.80M 77.30M 61.80M
Change to inventory 61.40M 8.80M 67.90M -260.50000M -14.00000M
Change to account receivables -23.39704M 14.80M 59.10M -80.90000M 12.10M
Sale purchase of stock -30.00000M -8.00000M -48.50000M -58.00000M -67.90000M
Other cashflows from financing activities -43.37597M -19.20000M -45.80000M -20.80000M 4.10M
Change to netincome - 15.10M 32.90M 46.70M 29.50M
Capital expenditures 62.80M 67.30M 72.60M 82.70M 64.80M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital 37.60M -46.63450M -51.85680M -172.70562M 43.44M
Stock based compensation 6.20M -5.50000M -2.60000M 30.10M 10.30M
Other non cash items 76.83M 22.23M 47.15M 16.29M 16.65M
Free cash flow 195.01M 113.20M 149.40M 90.10M 226.10M

Peer Comparison

Sector: Healthcare Industry: Medical Instruments & Supplies

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
ANSLF
Ansell Limited		 - -% 18.00 35.25 21.93 1.95 1.60 1.91 15.30
ISRG
Intuitive Surgical Inc		 -2.795 0.50% 560.80 73.05 61.73 19.15 10.25 18.41 59.92
ESLOY
Essilor International SA		 0.94 0.64% 146.88 35.39 24.81 3.63 2.20 4.00 16.25
ESLOF
EssilorLuxottica Société anonyme		 2.14 0.73% 296.00 35.71 25.13 3.62 2.23 4.00 16.25
BDX
Becton Dickinson and Company		 0.96 0.55% 176.37 37.72 15.92 3.25 2.49 4.08 17.10

Reports Covered

Stock Research & News

View All

Profile

Ansell Limited designs, sources, develops, manufactures, distributes, and sells hand and body protection solutions in the Asia Pacific, Europe, the Middle East, Africa, Latin America, the Caribbean, and North America. It operates in two segments, Healthcare and Industrial. The Healthcare segment manufactures and markets solutions comprising surgical gloves, single use and examination gloves, and clean and sterile gloves and garments, as well as consumables for hospitals, surgical centers, dental surgeries, veterinary clinics, first responders, manufacturers, auto repair shops, chemical plants, laboratories, and life sciences and pharmaceutical companies. The Industrial segment manufactures and markets hand and chemical protective clothing solutions for a range of industrial applications, including automotive, chemical, metal fabrication, machinery and equipment, food, construction, mining, oil and gas, utilities, logistics, and first responders. The company was formerly known as Pacific Dunlop Limited and changed its name to Ansell Limited in 2002. Ansell Limited was founded in 1893 and is based in Richmond, Australia.

Ansell Limited

678 Victoria Street, Richmond, VIC, Australia, 3121

Key Executives

Name Title Year Born
Mr. Neil I. Salmon ACMA, BA MD, CEO & Director 1969
Mr. Zubair Javeed Chief Financial Officer NA
Mr. Darryl Nazareth Pres of Healthcare GBU NA
Mr. Rikard Fröberg MA, MS Pres of the Industrial Global Bus. Unit (IGBU) NA
Mr. John Marsden Sr. VP of Global Operations & Global Supply Chain NA
Ms. Deanna Johnston Sr. VP & Global Chief Information Officer NA
Michael Evans Director of Corp. Devel. & Investor Relation NA
Mr. Michael Gilleece Sr. VP & Corp. Gen. Counsel NA
Ms. Amanda Manzoni Chief HR Officer NA
Mr. Francois Le Jeune BS, MBA, MS Chief Commercial Officer of EMEA, APAC & Guardian Admin. NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.